Pharmaceutical composition for the treatment of cystic fibrosis
AssigneeGalenus G.H. AG
InventorsRita DOBMEYER, Kurt NABER
Life of this patent
Estimating the term…
Abstract
The invention relates to a pharmaceutical composition comprising a polymyxin or a pharmaceutically acceptable salt or prodrug thereof, teicoplanin and/or fusidic acid or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient and to ready-to-use kits for the preparation of said pharmaceutical composition.
Claims17
-15. (canceled)
A method for the treatment of a bacterial lung infection associated with cystic fibrosis in a patient in need thereof comprising administering to the patient in need thereof:
- (a) a polymyxin or a pharmaceutically acceptable salt or prodrug thereof;
- and
- (b) at least one additional agent chosen from teicoplanin or a pharmaceutically acceptable salt or prodrug thereof, fusidic acid or a pharmaceutically acceptable salt or prodrug thereof, or combinations thereof.
A method for the treatment of a patient suffering from a bacterial infection, comprising administering to the patient synergistically effective amounts of
- (a) a polymyxin selected from polymyxin B or a pharmaceutically acceptable salt or prodrug thereof, polymyxin E (colistin) or a pharmaceutically acceptable salt or prodrug thereof, or combinations thereof;
- and
- (b) fusidic acid or a pharmaceutically acceptable salt or prodrug thereof, wherein the bacterial infections are caused by one or more Gram-negative bacteria selected from the group consisting of Stenotrophomonas maltophilia, Acinetobacter calcoaceticus, Acinetobacter guillouiae, Acinetobacter haemolyticus, Acinetobacter johnsonii, Acinetobacter junii, Acinetobacter lwoffii, Acinetobacter nosocomialis, Acinetobacter pitii, Acinetobacter radioresistens, Acinetobacter tjernbergiae, Acinetobacter ursingi, or combinations thereof.
Dependencies are inferred from the claim text.